New drug combo aims to fight lung cancer without chemo
NCT ID NCT06322108
First seen Jun 09, 2026 · Last updated Jun 20, 2026 · Updated 4 times
Summary
This phase 2 trial is testing whether a combination of two immunotherapy drugs, balstilimab and botensilimab, is safe and effective as a first treatment for people with metastatic non-small cell lung cancer (NSCLC) who have not had prior therapy for advanced disease. The study will enroll 45 participants and measure how many are alive without their cancer growing after 12 months. The drugs work by helping the immune system recognize and attack cancer cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hematology Center named after prof. R. Yeolyan
Yerevan, 0014, Armenia
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
balstilimab and botensilimab (immunotherapy drugs)
What this could lead to
If successful, this combination could offer a new first-line treatment option for people with metastatic non-small cell lung cancer, potentially helping them live longer without their cancer growing.
What could go wrong
This is a small, early-phase (Phase 2) trial with only 45 participants. The drugs may not work as hoped, or side effects could be serious. Results may not apply to all lung cancer patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.